Clinical Trial Update: Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating the safety of CG-P5 peptide eye drops in patients with age-related macular degeneration and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• CG-P5 peptide eye drops (CG-P5)

Snippet

Sponsor: Caregen Co. Ltd. | Conditions: Age-related Wet Macular Degeneration | Phase 1 | Status: RECRUITING